Entecavir versus tenofovir disoproxil fumarate on the reduction of incidence of hepatocellular carcinoma in patients with chronic hepatitis B-related liver cirrhosis

IF 0.3 Q4 GASTROENTEROLOGY & HEPATOLOGY

Advances in Digestive Medicine Pub Date : 2023-03-24 DOI:10.1002/aid2.13362

Yu-Hung Lin, Huang-Lun Lai, Chun-Hsiang Wang, Kuo-Kuan Chang, Lein-Ray Mo, Ruey-Chang Lin

{"title":"Entecavir versus tenofovir disoproxil fumarate on the reduction of incidence of hepatocellular carcinoma in patients with chronic hepatitis B-related liver cirrhosis","authors":"Yu-Hung Lin, Huang-Lun Lai, Chun-Hsiang Wang, Kuo-Kuan Chang, Lein-Ray Mo, Ruey-Chang Lin","doi":"10.1002/aid2.13362","DOIUrl":null,"url":null,"abstract":"<p>This study aimed to compare the effect of long-term continuous entecavir (ETV) compared with tenofovir disoproxil fumarate (TDF) on the reduction of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB) related liver cirrhosis. This study recruited patients who had CHB-related liver cirrhosis and received ETV or TDF treatment for more than 6 months. Regular assessments of ultrasonography and alpha-fetoprotein test were arranged every 3 months for HCC detection. Five-year cumulative incidence of HCC and risk factors for HCC development were analyzed. A total of 286 consecutive cirrhotic patients were included, 198 in the ETV group and 88 in the TDF group. During a median follow-up of 57.5 months, 25 (12.6%) patients in the ETV group and 12 (13.6%) patients in the TDF group developed HCC. The 5-year cumulative incidence of HCC was comparable between the ETV and TDF groups (6.57% vs. 9.09%, log-rank <i>p</i> = .242). Multivariate Cox proportional hazard analysis revealed that male, old age, diabetes, and low platelet count were independent risk factors for HCC development. This study observed that long-term ETV or TDF provided comparable preventive effects on HCC development in patients with CHB-related liver cirrhosis.</p>","PeriodicalId":7278,"journal":{"name":"Advances in Digestive Medicine","volume":"11 1","pages":"16-23"},"PeriodicalIF":0.3000,"publicationDate":"2023-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/aid2.13362","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Digestive Medicine","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/aid2.13362","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This study aimed to compare the effect of long-term continuous entecavir (ETV) compared with tenofovir disoproxil fumarate (TDF) on the reduction of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB) related liver cirrhosis. This study recruited patients who had CHB-related liver cirrhosis and received ETV or TDF treatment for more than 6 months. Regular assessments of ultrasonography and alpha-fetoprotein test were arranged every 3 months for HCC detection. Five-year cumulative incidence of HCC and risk factors for HCC development were analyzed. A total of 286 consecutive cirrhotic patients were included, 198 in the ETV group and 88 in the TDF group. During a median follow-up of 57.5 months, 25 (12.6%) patients in the ETV group and 12 (13.6%) patients in the TDF group developed HCC. The 5-year cumulative incidence of HCC was comparable between the ETV and TDF groups (6.57% vs. 9.09%, log-rank p = .242). Multivariate Cox proportional hazard analysis revealed that male, old age, diabetes, and low platelet count were independent risk factors for HCC development. This study observed that long-term ETV or TDF provided comparable preventive effects on HCC development in patients with CHB-related liver cirrhosis.

Abstract Image

查看原文本刊更多论文

恩替卡韦与富马酸替诺福韦降低慢性乙型肝炎相关肝硬化患者肝细胞癌发病率的比较

本研究旨在比较长期持续服用恩替卡韦（ETV）与富马酸替诺福韦二吡呋酯（TDF）对降低慢性乙型肝炎（CHB）相关肝硬化患者肝细胞癌（HCC）发病率的影响。这项研究招募了患有 CHB 相关肝硬化并接受 ETV 或 TDF 治疗超过 6 个月的患者。为检测 HCC，每 3 个月进行一次超声波检查和甲胎蛋白检测。对 HCC 的五年累积发病率和 HCC 发生的危险因素进行了分析。共纳入了286例连续肝硬化患者，其中ETV组198例，TDF组88例。在中位随访 57.5 个月期间，ETV 组有 25 例（12.6%）患者发生了 HCC，TDF 组有 12 例（13.6%）患者发生了 HCC。ETV 组和 TDF 组的 5 年累积 HCC 发生率相当（6.57% vs. 9.09%，log-rank p = .242）。多变量 Cox 比例危险分析显示，男性、高龄、糖尿病和血小板计数低是 HCC 发生的独立危险因素。本研究观察到，长期服用ETV或TDF对CHB相关肝硬化患者的HCC发展具有相似的预防效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Digestive Medicine GASTROENTEROLOGY & HEPATOLOGY-

自引率

33.30%

发文量

期刊介绍： Advances in Digestive Medicine is the official peer-reviewed journal of GEST, DEST and TASL. Missions of AIDM are to enhance the quality of patient care, to promote researches in gastroenterology, endoscopy and hepatology related fields, and to develop platforms for digestive science. Specific areas of interest are included, but not limited to: • Acid-related disease • Small intestinal disease • Digestive cancer • Diagnostic & therapeutic endoscopy • Enteral nutrition • Innovation in endoscopic technology • Functional GI • Hepatitis • GI images • Liver cirrhosis • Gut hormone • NASH • Helicobacter pylori • Cancer screening • IBD • Laparoscopic surgery • Infectious disease of digestive tract • Genetics and metabolic disorder • Microbiota • Regenerative medicine • Pancreaticobiliary disease • Guideline & consensus.